Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Du, Mulong ^a   Shi, Danni ^a   Yuan, Lin ^b   Li, Pengchao ^a   Chu, Haiyan ^a,c   Qin, Chao ^a   Yin, Changjun ^a   Zhang, Zhengdong ^a,c   Wang, Meilin ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c Nanjing Medical University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN497 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; BLOOD; CASE CONTROL STUDY; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; URINARY BLADDER NEOPLASMS;

ADULT; AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE; URINARY BLADDER NEOPLASMS;

EID: 84934880867     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10437     Document Type: Article

References (41)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J Clin 63, 11-30 (2013).
3. Mitra, A. P. & Cote, R. J. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 4, 251-85 (2009).
4. Latini, D. M., Lerner, S. P., Wade, S. W., Lee, D. W. & Quale, D. Z. Bladder cancer detection, treatment and outcomes: opportunities and challenges. Urology 75, 334-9 (2010).
5. Lokeshwar, V. B. et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66, 35-63 (2005).
6. Vrooman, O. P. & Witjes, J. A. Urinary markers in bladder cancer. Eur Urol 53, 909-16 (2008).
7. Bryan, R. T., Zeegers, M. P., James, N. D., Wallace, D. M. & Cheng, K. K. Biomarkers in bladder cancer. BJU Int 105, 608-13 (2010).
8. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-97 (2004).
9. Ambros, V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113, 673-6 (2003).
10. Bartels, C. L. & Tsongalis, G. J. MicroRNAs: novel biomarkers for human cancer. Clin Chem 55, 623-31 (2009).
11. Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nat Rev Cancer 6, 857-66 (2006).
12. Wang, M. et al. Genetic variants in miRNAs predict bladder cancer risk and recurrence. Cancer Res 72, 6173-82 (2012).
13. Ichimi, T. et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125, 345-52 (2009).
14. Dyrskjot, L. et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69, 4851-60 (2009).
15. Kopreski, M. S., Benko, F. A., Kwak, L. W. & Gocke, C. D. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res 5, 1961-5 (1999).
16. Li, Y., Zhou, X., St John, M. A. & Wong, D. T. RNA profiling of cell-free saliva using microarray technology. J Dent Res 83, 199-203 (2004).
17. Lawrie, C. H. et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141, 672-5 (2008).
18. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105, 10513-8 (2008).
19. Redova, M. et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 10, 55 (2012).
20. Adam, L. et al. Plasma microRNA profiles for bladder cancer detection. Urol Oncol 31, 1701-8 (2013).
21. Scheffer, A. R. et al. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol 32, 353-8 (2014).
22. Marrero, J. A. et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137, 110-8 (2009).
23. Balk, S. P., Ko, Y. J. & Bubley, G. J. Biology of prostate-specific antigen. J Clin Oncol 21, 383-91 (2003).
24. Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11, 426-37 (2011).
25. Gildea, J. J., Carlson, J. M., Schoeffel, C. D., Carey, R. M. & Felder, R. A. Urinary exosome miRNome analysis and its applications to salt sensitivity of blood pressure. Clin Biochem 46, 1131-4 (2013).
26. Hu, Z. et al. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 33, 828-34 (2012).
27. Zhu, W., Qin, W., Atasoy, U. & Sauter, E. R. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2, 89 (2009).
28. Resnick, K. E. et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112, 55-9 (2009).
29. Ng, E. K. et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375-81 (2009).
30. Luo, M., Shen, D., Zhou, X., Chen, X. & Wang, W. MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery 153, 836-47 (2013).
31. Yang, C. et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 132, 116-27 (2013).
32. Guo, S. T. et al. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 32, 1910-20 (2013).
33. Zaravinos, A., Volanis, D., Lambrou, G. I., Delakas, D. & Spandidos, D. A. Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol Rep 28, 1159-66 (2012).
34. Itesako, T. et al. The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. PLoS One 9, e84311 (2014).
35. Lehmann, U. et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 214, 17-24 (2008).
36. Shi, Y. et al. Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. Clin Cancer Res 20, 1803-13 (2014).
37. Pan, J. et al. Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells. Oncol Rep 24, 105-12 (2010).
38. Yi, C. et al. MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene 31, 4421-33 (2012).
39. Ralfkiaer, U. et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 118, 5891-900 (2011).
40. Pirola, C. J. et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut doi: 10.1136/gutjnl-2014-306996 (2014).
41. Zampetaki, A. et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107, 810-7 (2010).